Behçet's syndrome pathophysiology and potential therapeutic targets

Internal and Emergency Medicine

Volumn 9, Issue 3, 2014, Pages 257-265

  Emmi, Giacomo ^b   Silvestri, Elena ^a,b   Squatrito, Danilo ^a   D'Elios, Mario Milco ^a,b   Ciucciarelli, Lucia ^b   Prisco, Domenico ^a,b   Emmi, Lorenzo ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anti TNF ; Beh et syndrome pathophysiology; Beh et treatment; Biologic therapy; IL 1 blocking agents

Indexed keywords

BEHCET SYNDROME; HUMAN; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

BEHCET SYNDROME; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84897023712     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-013-1036-5     Document Type: Review

References (74)

1. Emmi L (2014) Behçet's syndrome: from pathogenesis to treatment. Springer (in press).
2. Gul A, Ohno S (2012) HLA-B*51 and Behçet disease. Ocular Immunol Inflamm 20: 37-43.
3. Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR (1999) Behçet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 54: 213-220.
4. Meguro A, Inoko H, Ota M, Katsuyama Y, Oka A, Okada E, Yamakawa R, Yuasa T, Fujioka T, Ohno S, Bahram S, Mizuki N (2010) Genetics of Behçet's disease inside and outside the MHC. Ann Rheum Dis 69: 747-754.
5. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, Le JM, Yang B, Korman BD, Cakiris A, Aglar O, Emrence Z, Azakli H, Ustek D, Tugal-Tutkun I, Akman-Demir G, Chen W, Amos CI, Dizon MB, Kose AA, Azizlerli G, Erer B, Brand OJ, Kaklamani VG, Kaklamanis P, Ben-Chetrit E, Stanford M, Fortune F, Ghabra M, Ollier WE, Cho YH, Bang D, O'Shea J, Wallace GR, Gadina M, Kastner DL, Gül A (2010) Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet 42(8): 698-702.
6. Hou S, Yang Z, Du L, Jiang Z, Shu Q, Chen Y, Li F, Zhou Q, Ohno S, Chen R, Kijlstra A, Rosenbaum JT, Yang P (2012) Identification of a susceptibility locus in STAT4 for Behçet's disease in Han Chinese in a genome-wide association study. Arthritis Rheum 64: 4104-4113.
7. Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, Ozyazgan Y, Sacli FS, Erer B, Inoko H, Emrence Z, Cakar A, Abaci N, Ustek D, Satorius C, Ueda A, Takeno M, Kim Y, Wood GM, Ombrello MJ, Meguro A, Gül A, Remmers EF, Kastner DL (2013) Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 45: 202-207.
8. Kirino Y, Zhou Q, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, Özyazgan Y, Ugurlu S, Erer B, Abaci N, Ustek D, Meguro A, Ueda A, Takeno M, Inoko H, Ombrello MJ, Satorius CL, Maskeri B, Mullikin JC, Sun HW, Gutierrez-Cruz G, Kim Y, Wilson AF, Kastner DL, Gül A, Remmers EF (2013) Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behçet disease. Proc Natl Acad Sci USA 110(20): 8134-8139.
9. Mizushima Y, Matsuda T, Hoshi K, Ohno S (1988) Induction of Behçet's disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol 15: 1029-1030.
10. Mumcu G, Inanc N, Aydin SZ, Ergun T, Direskeneli H (2009) Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Behçet's disease. Clin Exp Rheumatol 27: S32-S36.
11. Tojo M, Yanagihori H, Zheng X, Oyama N, Isogai E, Nakamura K, Kaneko F (2003) Detection of microbial DNA in skin lesions from patients with Behçet's disease. Adv Exp Med Biol 528: 185-190.
12. Yokota K, Hayashi S, Araki Y, Isogai E, Kotake S, Yoshikawa K, Fujii N, Hirai Y, Oguma K (1995) Characterization of Streptococcus sanguis isolated from patients with Behçet's disease. Microbiol Immunol 39: 729-732.
13. The Behçet's Disease Research Committee of Japan (1989) Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behçet's disease-a multicenter study. J Rheumatol 16: 506-511.
14. Togashi A, Saito S, Kaneko F, Nakamura K, Oyama N (2011) Skin prick test with self-saliva in patients with oral aphthoses: a diagnostic pathergy for Behçet's disease and recurrent aphthosis. Inflamm Allergy Drug Targets 10(3): 164-170.
15. Benagiano M, D'Elios MM, Amedei A, Azzurri A, van der Zee R, Ciervo A, Rombolà G, Romagnani S, Cassone A, Del Prete G (2005) Human 60-kDa heat shock protein is a target autoantigen of T cells derived from atherosclerothique plaques. Immunol 174: 6509-6517.
16. Lehner T (1997) The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease. Int Rev Immunol 14: 21-32.
17. Hatemi G, Yazici H (2011) Behçet syndrome and infections. Best Pract Res Clin Rheum 25: 389-406.
18. Uchio E, Stanford M, Hasan A, Satoh S, Ohno S, Shinnick T, van der Zee R, Mizushima Y, Lehner T (1998) HSP-derived peptides inducing uveitis and IgG and IgA antibodies. Exp Eye Res 67: 719-727.
19. Kaneko F, Oyama N, Yanagihori H, Isogai E, Yokota K, Oguma K (2008) The role of streptococcal hypersensitivity in the pathogenesis of Behçet's disease. Eur J Dermatol 18: 489-498.
20. Shaker O, Ay El-Deen MA, El Hadidi H, Grace BD, El Sherif H, Abdel Halim A (2007) The role of heat shock protein 60, vascular endothelial growth factor and antiphospholipid antibodies in Behçet disease. Br J Dermatol 156: 32-37.
21. Mochizuki M, Suzuki N, Takeno M, Nagafuchi H, Harada T, Kaneoka H, Yamashita N, Hirayama K, Nakajima T, Mizushima Y (1994) Fine antigen specificity of human gamma delta T cell lines (V gamma 9 +) established by repetitive stimulation with a serotype (KTH-1) of a gram-positive bacterium, Streptococcus sanguis. Eur J Immunol 24: 1536-1543.
22. Bank I, Duvdevani M, Livneh A (2003) Expansion of gammadelta T-cells in Behçet's disease: role of disease activity and microbial flora in oral ulcers. J Lab Clin Med 141: 33-40.
23. Hirohata S, Oka H, Mizushima Y (1992) Streptococcal related antigens stimulate production of IL-6 and interferon-gamma by T cells from patients with Behçet's disease. Cell Immunol 140: 410-419.
24. Pay S, Simşek I, Erdem H, Dinç A (2007) Immunopathogenesis of Behçet's disease with special emphasize on the possible role of antigen presenting cells. Rheumatol Int 27: 417-424.
25. Zhou ZY, Chen SL, Lu Y (2012) Cytokines and Behcet's disease. Autoimmun Rev 11: 699-704.
26. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D (2012) New insights into the pathogenesis of Behçet's disease. Autoimmun Rev 11: 687-698.
27. Geri G, Terrier B, Rosenzwajg M, Wechsler B, Touzot M, Seilhean D, Tran TA, Bodaghi B, Musset L, Soumelis V, Klatzmann D, Cacoub P, Saadoun D (2011) Critical role of IL-21 in modulating Th17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol 128: 655-664.
28. Song YW, Kang EH (2012) Behcet's disease and genes within the major histocompatibility complex region. Mod Rheumatol 22: 178-185.
29. Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T (2001) Neutrophil activation in Behçet's disease. Clin Exp Rheumatol 19: S19-S24.
30. Buldanlioglu S, Turkmen S, Ayabakan HB, Yenice N, Vardar M, Dogan S, Mercan E (2005) Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet's disease. Br J Dermatol 153: 526-530.
31. Croft M, Benedict CA, Ware CF (2013) Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 12(2): 147-168.
32. Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, Ocal L, Inanç M, Capo C (1993) Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20: 1544-1549.
33. Triolo G, Accardo-Palumbo A, Dieli F, Ciccia F, Ferrante A, Giardina E, Sano CD, Licata G (2003) Vgamma9/Vdelta2 T lymphocytes in Italian patients with Behçet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease. Arthritis Res Ther 5: R262-R268.
34. Freysdottir J, Hussain L, Farmer I, Lau SH, Fortune F (2006) Diversity of gammadelta T cells in patients with Behçet's disease is indicative of polyclonal activation. Oral Dis 12: 271-277.
35. Accardo-Palumbo A, Giardina AR, Ciccia F, Ferrante A, Principato A, Impastato R, Giardina E, Triolo G (2010) Phenotype and functional changes of Vgamma9/Vdelta2 T lymphocytes in Behçet's disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansion, activation and cytotoxicity. Arthritis Res Ther 12: R109.
36. de Vos AF, van Haren MA, Verhagen C, Hoekzema R, Kijlstra A (1994) Kinetics of intraocular tumor necrosis factor and interleukin 6 in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 35: 1100-1106.
37. Köse O (2012) Development of immunopathogenesis strategies to treat Behçet's disease. Patholog Res Int 2012: 261989.
38. Mesquida M, Molins B, Llorenç V, Hernández MV, Espinosa G, Dick AD, Adán A (2013) Current and future treatments for Behçet's uveitis: road to remission. Int Ophthalmol. doi: 10. 1007/s10792-013-9788-5.
39. Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, Tanaka Y (2009) Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behçet's disease. Rheumatology (Oxford) 48: 1012-1013.
40. Giardina A, Ferrante A, Ciccia F, Vadalà M, Giardina E, Triolo G (2011) One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs. Rheumatol Int 31: 33-37.
41. Perra D, Alba MA, Callejas JL, Mesquida M, Ríos-Fernández R, Adán A, Ortego N, Cervera R, Espinosa G (2012) Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford) 51: 1825-1831.
42. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Hamuryudan V, Yazici H (2005) Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 32: 98-105.
43. Mesquida M, Victoria Hernández M, Llorenç V, Pelegrín L, Espinosa G, Dick AD, Adán A (2013) Behçet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm 21(2): 160-162.
44. Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11(8): 633-652.
45. Hamzaoui K, Hamza M, Ayed K (1990) Production of TNF-alpha and IL-1 in active Behçet's disease. J Rheumatol 17(10): 1428-1429.
46. Pay S, Erdem H, Pekel A, Simsek I, Musabak U, Sengul A, Dinc A (2006) Synovial proinflammatory cytokines and their correlation with matrixmetalloproteinase-3 expression in Behçet's disease. Does interleukin-1b play a major role in Behçet's synovitis? Rheumatol Int 27: 608-613.
47. Karasneh J, Hajeer AH, Barrett J, Ollier WE, Thornhill M, Gul A (2003) Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behçet's disease. Rheumatology (Oxford) 42: 860-864.
48. Akman A, Ekinci NC, Kacaroglu H, Yavuzer U, Alpsoy E, Yegin O (2008) Relationship between periodontal findings and specific polymorphisms of interleukin-1alpha and -1beta in Turkish patients with Behçet's disease. Arch Dermatol Res 300: 19-26.
49. Gül A (2005) Behçet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 4: 81-83.
50. Ishigatsubo Y, Samukawa S (2011) Behçet's disease from the aspect of autoinflammatory disease. Nihon Rinsho Meneki Gakkai Kaishi 34: 408-419.
51. Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA (2008) Resistant Behçet disease responsive to anakinra. Ann Intern Med 149(4): 284-286.
52. Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, Scannon P, Solinger A (2012) Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Ann Rheum Dis 71: 563-566.
53. Emmi G, Silvestri E, Cameli A, Bacherini D, Vannozzi L, Squatrito D, Emmi L (2013) Anakinra for resistant Behçet uveitis: why not? Clin Exp Rheumatol 31(3Suppl. 77): 152-153.
54. Adam B, Calikoglu E (2004) Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behçet's disease. J Eur Acad Dermatol Venereol 18: 318-320.
55. Nalbant S, Sahan B, Durna M, Ersanli D, Kaplan M, Karabudak O, Unal M (2008) Cytokine profile in Behçet uveitis. Bratisl Lek Listy 109: 551-554.
56. Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, Ishigatsubo Y (2012) Clinical characteristics of neuro-Behçet's disease in Japan: a multicenter retrospective analysis. Mod Rheumatol 22: 405-413.
57. Borhani Haghighi A, Safari A (2008) Tocilizumab may be a potential addition to our weapons against neuro-Behçet's disease. Med Hypotheses 71(1): 156-157.
58. Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M, Ogata A, Yoshizaki K, Kumanogoh A, Kishimoto T, Tanaka T (2012) A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 22: 298-302.
59. Shapiro LS, Farrell J, Haghighi AB (2012) Tocilizumab treatment for neuro-Behçet's disease, the first report. Clin Neurol Neurosurg 114: 297-298.
60. Urbaniak P, Hasler P, Kretzschmar S (2012) Refractory neuro-Behçet treated by tocilizumab: a case report. Clin Exp Rheumatol 30(3 Suppl 72): S73-S75.
61. Pestka S, Krause CD, Walter MR (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202: 8-32.
62. Liu X, Yang P, Wang C, Li F, Kijlstra A (2011) IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behçet's disease. Rheumatology (Oxford) 50: 293-298.
63. Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, Basaran E (2002) Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 138: 467-471.
64. Kötter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Günaydin I, Grimbacher B, Blaschke S, Meyer-Riemann W, Peter HH, Stübiger N (2003) Human recombinant interferon alpha-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87: 423-431.
65. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M (2006) Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol 244: 1692-1695.
66. Onal S, Kazokoglu H, Koc A, Akman M, Bavbek T, Direskeneli H, Yavuz S (2011) Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol 129: 288-294.
67. Hamzaoui K, Houman H, Hentati F, Hamzaoui A (2008) BAFF is up-regulated in central nervous system of neuro-Behçet's disease. J Neuroimmunol 200: 111-114.
68. Hamzaoui K, Houman H, Ben Dhifallah I, Kamoun M, Hamzaoui A (2008) Serum BAFF levels and skin mRNA expression in patients with Behçet's disease. Clin Exp Rheumatol 26(50): S64-S71.
69. Hamzaoui A, Chelbi H, Sassi FH, Hamzaoui K (2010) Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behçet's disease with pulmonary involvement. Oxid Med Cell Longev 3: 122-128.
70. Fairfax K, Mackay IR, Mackay F (2012) BAFF/BLyS inhibitors: a new prospect for treatment of systemic lupus erythematosus. UBMB Life 64(7): 595-602.
71. Danés I, Agustí A, Vallano A, Martínez J, Alerany C, Ferrer A, López A, Cortés-Hernández J, Bosch JA (2013) Available evidence and outcome of off-label use of rituximab in clinical practice. Eur J Clin Pharmacol 69(9): 1689-1699.
72. Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A, Chams-Davatchi C, Akhlaghi M, Faezi T, Naderi N (2010) Rituximab in intractable ocular lesions of Behçet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 13: 246-252.
73. Day ES, Cachero TG, Qian F, Sun Y, Wen D, Pelletier M, Hsu YM, Whitty A (2005) Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 44: 1919-1931.
74. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L, Sturm B, Poortman C, Minter RR, Dobson CL, Williams E, Carmen S, Smith R, Roschke V, Hilbert DM, Vaughan TJ, Albert VR (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B Lymphocyte Stimulator. Arthritis Rheum 48: 3253-3265.